文献速递血液净化与透析肾血管病与高血压

帕立骨化醇治疗的血液透析患者ADMA水平较低

Asymmetric Dimethylarginine (ADMA) Levels Are Lower in Hemodialysis Patients Treated With Paricalcitol.
PubMed 文献 · Kidney Int Rep · 2016-10-18

该横断面分析探讨透析患者中与非对称二甲基精氨酸(ADMA)相关的因素,发现接受帕立骨化醇治疗者ADMA水平显著低于未治疗者(0.21±0.19 vs 0.42±0.35 μmol/l,P=0.00027),且帕立骨化醇剂量与ADMA呈负相关,其他药物无显著差异。

要点

  • 血液透析患者中,帕立骨化醇治疗与较低ADMA水平独立相关。
  • 帕立骨化醇剂量越高,ADMA水平越低(r=-0.36,P=0.013)。
  • 其他心血管药物与ADMA水平无显著关联。

核心结论

  • 接受帕立骨化醇治疗的血液透析患者ADMA水平显著低于未接受者。
  • 帕立骨化醇与ADMA及一氧化氮合成相关的心血管获益机制尚不明确。

研究设计与样本

  • 横断面分析,旨在识别透析患者中与ADMA相关的因素(包括心血管相关药物)。

主要发现

  • 帕立骨化醇治疗者ADMA为0.21±0.19 μmol/l,未治疗者为0.42±0.35 μmol/l(P=0.00027)。
  • 按ADMA四分位分组,帕立骨化醇治疗者出现极高ADMA水平的可能性更低(P=0.014)。
  • 其他药物与ADMA水平无显著差异。
  • 帕立骨化醇剂量与ADMA水平呈负相关(r=-0.36,P=0.013)。

临床怎么用

  • 在血液透析患者中,帕立骨化醇治疗可能与较低的ADMA水平相关,但需进一步研究确认其心血管获益。

局限性

  • 横断面设计无法确定因果关系。
  • 帕立骨化醇与ADMA及一氧化氮合成相关的心血管获益机制未知。
  • 需进一步研究确认效应并阐明病理生理机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic kidney disease is a major public health problem. In the last decade, it has been shown that the early stages of chronic kidney disease are associated with an inflammatory condition involving an increased risk of cardiovascular morbidity and long-term mortality. In patients with chronic kidney disease and more specifically those on hemodialysis, cardiovascular events are the most common cause of death. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase and may be an independent risk factor for endothelial dysfunction and cardiovascular disease. METHODS: We performed a cross-sectional analysis to identify factors that were associated with ADMA such as certain medications related to cardiovascular disease in dialysis patients. RESULTS: Patients who were treated with paricalcitol had significantly lower levels of ADMA (0.21 ± 0.19 μmol/l) compared with those not treated with paricalcitol (0.42 ± 0.35 μmol/l) (P = 0.00027). Dividing ADMA levels by quartiles, patients treated with paricalcitol were less likely to have very high level ADMA (P = 0.014), whereas there were no significant differences with other medications. Higher dose of paricalcitol was also related to lower levels of ADMA noting an inverse correlation (r = -0.36, P = 0.013). DISCUSSION: Hemodialysis patients treated with paricalcitol presented significantly decreased ADMA levels compared with those who did not receive this treatment. Possible beneficial effects in terms of cardiovascular morbidity and mortality by paricalcitol and its association with ADMA and nitric oxide synthesis are unknown. Studies to confirm this effect and determine the underlying pathophysiological mechanism are necessary.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Oliva-Damaso E, Oliva-Damaso N, Rodriguez-Esparragon F, et al. Asymmetric Dimethylarginine (ADMA) Levels Are Lower in Hemodialysis Patients Treated With Paricalcitol. Kidney Int Rep. 2016. PMID: 29142954. doi:10.1016/j.ekir.2016.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。